Finance

Lists
Outlook: 36.4% bullish·13.6% bearish
Go to analysis
GSK:NYSE
GSK plc
$49.49
-0.04%
(-0.020) 1D
Oct 19, 1:05:26 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GSK...
Open
$49.44
High
$49.81
Low
$49.26
Mkt. cap
99.97B
Avg. vol.
4.64M
Volume
2.84M
Dividend
3.67%
Quarterly dividend
$0.45
Ex-dividend date
Aug 13, 2026
P/E ratio
15.73
52-wk high
$61.70
52-wk low
$42.84
EPS
$3.15
Beta
0.25
Shares outstanding
2.16B
No. of employees
67K
Open
$49.44
High
$49.81
Low
$49.26
Mkt. cap
99.97B
Avg. vol.
4.64M
Volume
2.84M
Dividend
3.67%
Quarterly dividend
$0.45
Ex-dividend date
Aug 13, 2026
P/E ratio
15.73
52-wk high
$61.70
52-wk low
$42.84
EPS
$3.15
Beta
0.25
Shares outstanding
2.16B
No. of employees
67K
News stories
From web sources and news partners
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England. GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500. The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK. The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOEmma Walmsley | Emma Walmsley
Employees66.8K
FoundedDec 27, 2000
Headquarters-
SectorPharmaceutical industry
Websitegsk.com
Analyst ratings
Based on 2 analysts giving stock ratings to GSK in the past 3 months
Buy
Buy
1
Hold
1
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for GSK in the last 3 months.
Highest
Current $49.49
$70.00 (+41.44%)
Average
$65.00 (+31.34%)
Lowest
$60.00 (+21.24%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Berenberg Bank
Buy
Upgraded
$60.00
+21.2%
09/15/2026
Steve Scala
TD Cowen
Hold
Maintained
$70.00
+41.4%
08/03/2026
Jasper Hellweg
Argus Research
Buy
Maintained
-
-
06/08/2026
Michael Leuchten
Jefferies
Buy
Maintained
$67.10
+35.6%
05/29/2026
Unknown Analyst
Citi
Hold
Initiated
-
-
01/29/2026
Next call in 9 days
Wed, Oct 28, 2:00 PM
Fiscal period
Q3 2026
- / £1.33
Revenue / Est. (GBP)
- / 8.81B
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in GBP
Loading Previous Earnings...
Revenue
Net income
All values in GBP
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
8.55B
8.62B
7.63B
8.41B
Cost of goods sold
2.24B
2.62B
1.87B
2.07B
Cost of revenue
2.24B
2.62B
1.87B
2.07B
Research and development expenses
1.58B
2.14B
1.52B
1.75B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.16B
2.67B
2.08B
2.19B
Operating expense
3.23B
4.37B
2.99B
3.74B
Total operating expenses
5.46B
6.99B
4.86B
5.81B
Operating income
3.08B
1.63B
2.77B
2.60B
Other non operating income
-
-21.00M
-
-
EBT including unusual items
2.46B
950.00M
2.14B
354.00M
EBT excluding unusual items
2.94B
1.48B
2.62B
2.48B
Income tax expense
312.00M
223.00M
305.00M
-199.00M
Effective tax rate
12.70%
23.47%
14.23%
-56.21%
Other operating expenses
-511.00M
-434.00M
-615.00M
-204.00M
Net income
2.01B
636.00M
1.74B
435.00M
Net profit margin
23.55%
7.38%
22.77%
5.17%
Earnings per share
0.55
-
-
-
Interest and investment income
26.00M
17.00M
22.00M
58.00M
Interest expense
-167.00M
-145.00M
-167.00M
-182.00M
Net interest expenses
-141.00M
-128.00M
-145.00M
-124.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
3.82B
2.69B
3.23B
2.82B
Gain or loss from assets sale
-
-40.00M
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps